Literature DB >> 12426861

[Phytotherapy of benign prostatic hyperplasia. Current evidence-based evaluation].

K Dreikorn1, R Berges, L Pientka, U Jonas.   

Abstract

Despite its popularity as a medication in various European countries or as a nutritional supplement in the United States, the role of plant extracts for the treatment of LUTS due to BPH remains controversial. Only a few randomized clinical trials that meet standard criteria of evidence-based medicine but with relatively short follow-up times and some meta-analyses mainly regarding Serenoa repens and Pygeum Africanum as well as more recent studies on pumpkin seeds have shown clinical effects and good tolerability. To better judge the therapeutic potential of these plant extracts, additional randomized placebo-controlled clinical trials with sufficient follow-up are needed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12426861     DOI: 10.1007/s00120-002-0234-y

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  5 in total

Review 1.  [Phytotherapy for BPS. Which products can still be prescribed?].

Authors:  S Madersbacher; G Schatzl; C Brössner; K Dreikorn
Journal:  Urologe A       Date:  2005-05       Impact factor: 0.639

2.  [Phytotherapy of benign prostate syndrome and prostate cancer: better than placebo].

Authors:  C Wehrberger; K Dreikorn; B J Schmitz-Dräger; M Oelke; S Madersbacher
Journal:  Urologe A       Date:  2012-12       Impact factor: 0.639

Review 3.  [Drug therapy for benign prostatic hyperplasia. Systematic overview].

Authors:  R Berges; K Höfner
Journal:  Urologe A       Date:  2005-05       Impact factor: 0.639

4.  Phytosterol Pygeum africanum regulates prostate cancer in vitro and in vivo.

Authors:  Nader S Shenouda; Mary S Sakla; Leslie G Newton; Cynthia Besch-Williford; Norman M Greenberg; Ruth S MacDonald; Dennis B Lubahn
Journal:  Endocrine       Date:  2007-02       Impact factor: 3.633

5.  [Stinging nettle root extract (Bazoton-uno) in long term treatment of benign prostatic syndrome (BPS). Results of a randomized, double-blind, placebo controlled multicenter study after 12 months].

Authors:  T Schneider; H Rübben
Journal:  Urologe A       Date:  2004-03       Impact factor: 0.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.